MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-01-2026
Aspira Women's Health Net Income 2011-2026 | AWH
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Aspira Women's Health
| 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.8 M | -13.1 M | -27.2 M | -31.7 M | -17.9 M | -15.2 M | -11.4 M | -10.5 M | -15 M | -19.1 M | -19.2 M | -8.82 M | -7.15 M | -17.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.15 M | -31.7 M | -16.2 M |
Quarterly Net Income Aspira Women's Health
| 2025-Q3 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.89 M | -1.85 M | - | -3.55 M | -3.53 M | -4.63 M | - | -4.71 M | -2.32 M | -6.58 M | - | -7.78 M | -8.24 M | -9.27 M | - | -9.71 M | -7.07 M | -5.92 M | - | -4.29 M | -3.83 M | -3.71 M | - | -3.82 M | -4.31 M | -3.72 M | - | -2.65 M | -3.05 M | -2.85 M | - | -2.51 M | -2.36 M | -2.67 M | - | -3.48 M | -3.75 M | -4.9 M | - | -5.15 M | -4.85 M | -4.14 M | - | -5.59 M | -5.56 M | -3.99 M | - | -2.31 M | -2.12 M | -2.57 M | - | -2.02 M | -1.97 M | -1.78 M | - | -4.65 M | -5.71 M | -4.29 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.78 M | -9.71 M | -4.29 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Co-Diagnostics
CODX
|
-46.9 M | $ 1.67 | - | $ 2.22 M |  USA |
 |
Castle Biosciences
CSTL
|
18.2 M | $ 24.46 | - | $ 679 M | USA |
 |
Agilent Technologies
A
|
1.21 B | $ 115.55 | - | $ 35.1 B | USA |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Illumina
ILMN
|
-1.22 B | $ 127.88 | - | $ 20.3 B | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Lantheus Holdings
LNTH
|
234 M | $ 84.33 | - | $ 5.69 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.1 M | - | - | $ 9.42 M |  Israel |
 |
Koninklijke Philips N.V.
PHG
|
3.32 B | $ 27.47 | - | $ 20 B |  Niderland |
 |
CareDx, Inc
CDNA
|
-21.4 M | $ 21.23 | - | $ 1.13 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
Senseonics Holdings
SENS
|
-69.1 M | $ 7.05 | - | $ 294 M | USA |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-208 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
-42.7 M | $ 16.31 | - | $ 493 M | USA |
 |
Thermo Fisher Scientific
TMO
|
6.7 B | $ 469.71 | - | $ 177 B | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M |  China |
 |
Trinity Biotech plc
TRIB
|
929 K | $ 0.65 | -1.84 % | $ 61.9 M |  Irlanda |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | China |
 |
Twist Bioscience Corporation
TWST
|
-77.7 M | $ 60.94 | - | $ 3.64 B | USA |
 |
Charles River Laboratories International
CRL
|
-144 M | $ 169.8 | - | $ 8.42 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
Guardant Health
GH
|
-416 M | $ 88.91 | - | $ 11.1 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
24.6 M | $ 1.98 | -2.37 % | $ 8.76 M | USA |
 |
Medpace Holdings
MEDP
|
451 M | $ 410.54 | - | $ 11.8 B | USA |
 |
Exagen
XGN
|
-20 M | $ 2.7 | 0.75 % | $ 58.2 M | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
425 M | - | - | $ 10.6 B | Niderland |
 |
Neogen Corporation
NEOG
|
-1.09 B | $ 9.54 | - | $ 2.07 B | USA |
 |
Biomerica
BMRA
|
-4.97 M | $ 2.14 | - | $ 4.92 M | USA |
 |
National Research Corporation
NRC
|
11.6 M | $ 17.23 | - | $ 386 M | USA |
 |
ICON Public Limited Company
ICLR
|
791 M | $ 102.17 | - | $ 8.43 B | Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
876 M | $ 263.8 | - | $ 21.9 B | USA |
 |
Celcuity
CELC
|
-177 M | $ 121.03 | - | $ 5.66 B | USA |
 |
OpGen
OPGN
|
12 M | - | -16.95 % | $ 1.54 M | USA |
 |
NeoGenomics
NEO
|
-108 M | $ 8.29 | - | $ 1.06 B | USA |
 |
Myriad Genetics
MYGN
|
-366 M | $ 4.78 | - | $ 443 M | USA |
 |
Natera
NTRA
|
-548 M | $ 203.75 | - | $ 20.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
992 M | $ 196.27 | - | $ 21.8 B | USA |
 |
Invitae Corporation
NVTA
|
-99.8 M | - | - | $ 21.2 M | USA |
 |
PerkinElmer
PKI
|
241 M | - | -0.91 % | $ 14.7 B | USA |